Aibili Logo Association for Innovation and Biomedical Research on Light

CORC // Coimbra Ophthalmology Reading Centre


Framework to Develop and Validate Automated Image Analysis Systems for Early Diagnosis and Treatment of Eyes at Risk in Blinding Age-Related Diseases. (FILTER) [more info]

Characterization of Retinal vascular disease in eyes with mild to moderate NPDR in Diabetes type 2, using novel non-invasive Imaging methods, in a longitudinal and prospective clinical Study with 2 years of duration. (CORDIS, Protocol CEC010/2018) [more info]

A Phase 2, randomised, single-masked, active-controlled, multicentre study to evaluate the efficacy and safety of intravitreal THR-317 when administered alone or in combination with Lucentis®, in diabetic macular oedema (DME) patients with a poor or no response to anti vascular endothelial growth factor (anti-VEGF) treatment. (Protocol THR-317-002) [more info]

A Phase 1/2a, Open-Label, Non-Randomized, Dose-Escalation Study to Evaluate the Safety and Tolerability of GS030 in Subjects with Retinitis Pigmentosa. (Protocol GS030_CLIN_001) [more info]

RetmarkerAMD Software Validation [more info]

Progression of Diabetic Retinopathy. Identification of Signs and Surrogate outcomes. (PROGRESS, Protocol CEC/007/16) [more info]

A Phase 2, single-masked, multicentre study to evaluate the safety and efficacy of 2 dose levels of THR-317 for the treatment of diabetic macular oedema (DME). (Protocol THR-317-001) [more info]

OCT-A (Optical Coherence Tomography Angiography): Evaluation and Comparison with FA. [more info]

AMD Incidance Central Portugal - Coimbra Eye Study: The five-year incidence of Age-Related Macular Degeneration. A clinical study with color fundus photography, optical coherence tomography and blood sample collection in Mira. (AMD Incidence_CPT, Protocol 4C-2016-09) [more info]

An open-label, randomized, active-controlled, parallel-group, Phase-3b study of the efficacy, safety, and tolerability of three different treatment regimens of 2 mg Eylea administered by intravitreal injections to subjects with diabetic macular edema (DME). (VIOLET, Protocol BAY 86-5321 / 17613) [more info]

An open-label, randomized, active-controlled, parallel-group, Phase-3b study of the efficacy, safety, and tolerability of 2 mg aflibercept administered by intravitreal injections using two different treatment regimens to subjects with neovascular age-related macular degeneration (nAMD). (AZURE, Protocol BAY 86-5321 / 16598) [more info]

A Randomized, Double-masked, Sham-controlled Phase 4 Study of the Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Monotherapy Compared to Aflibercept With Adjunctive Photodynamic Therapy in patients with Polypoidal Choroidal Vasculopathy. (ATLANTIC, Protocol ECR-AMD-2015-09) ) [more info]

DR Screening - central reading for pilot studies for Critical Health. [more info]

Neurodegeneration as an early event in the pathogenesis of Diabetic Retinopathy: A multicentric, prospective, phase II-III, randomised controlled trial to assess the efficacy of neuroprotective drugs administered topically to prevent or arrest Diabetic Retinopathy (EUROCONDOR, Protocol nº 4C-2011-02) [more info]

Diabetic Retinopathy Screening – Central Region of Portugal [more info]

Services

  • Development and provision of study-specific Acquisition Protocols
  • Technicians training and certification
  • Equipment certification
  • Web-based platform for exams’ submission
  • Development and application of study-specific Grading Protocols
  • Grading of ophthalmic exams (retinal fundus images, OCT, mfERG, …) by trained graders for characterization and quantification of ophthalmic disease
  • Eligibility review services
  • Management and  monitoring of exams received and results
  • Provides data backup procedures and a disaster recovery plan
  • Provides secure long-term archiving of study materials , both digital and hardcopy
  -   Cloud   -  Copyright © AIBILI   -   Contact Us   -   Site Map   -   Privacy Policy  -  Cookies Policy  -  Webdesign Glitz Design   -   Programming Bizview